Delivery Order SPE2DB22D2211-SPE2DB25FSFAP
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 6, 2025, for the supply of Ofev 150 mg capsules (60-count units) with a ceiling value of $8,590.58. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded to support federal medical procurement needs. The contract specifies performance in Conshohocken, Pennsylvania, with an ultimate completion date of August 27, 2025. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $17,181.16 to AmerisourceBergen Drug Corp for Ofev 150 mg capsules (60-count units) on August 14, 2025, with an ultimate completion date of September 5, 2025. This firm fixed-price contract represents a non-competitive delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.999 billion vehicle running through December 2026. The place of performance...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on August 6, 2025, for the supply of Ofev (nintedanib) 150 mg capsules in a quantity of 60 units, with a ceiling value of $8,590.58. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was competitively procured. The contract carries an ultimate completion date of August 27, 2025, and performance will be executed from the vendor's corporate office location in...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency on June 2, 2025, for the supply of Ofev (nintedanib) 150 mg capsules in quantities of 60 units. This is a firm fixed-price delivery order with a ceiling value of $8,590.58 and an ultimate completion date of June 24, 2025. The contract represents a non-competitive, non-set-aside award issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $43,032.32 by the Defense Logistics Agency (DLA) on July 24, 2025, for the supply of Ofev 150 mg capsules (60-count units). This is a competitively awarded, firm fixed-price contract with no set-aside designation and an ultimate completion date of August 14, 2025. The contract is classified as a child award under a larger vehicle, and performance will take place at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 2, 2025, for the supply of Ofev 150 mg capsules (60-count units) valued at $8,590.58 with a firm fixed price contract type. The award is non-set-aside and represents a competitive procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly supporting military...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 5, 2025, for the supply of Ofev 150 mg capsules (60-count units) valued at $17,181.16. This is a firm fixed-price delivery order with no set-aside designation, reflecting a competitively awarded contract. The order is due for completion by September 26, 2025, and will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $8,590.58 delivery order to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of OFEV 150 mg capsules (60-unit quantity). The contract, which is non-set-aside and competitively awarded, represents a firm fixed-price delivery order with an ultimate completion date of August 4, 2025. AmerisourceBergen will perform this work from its corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Ofev 100 mg capsules (60-count units) with a ceiling value of $17,260.58. This firm fixed-price delivery order, which is expected to be completed by September 2, 2025, represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. Ofev (nintedanib) is a medication...
- The Defense Logistics Agency (DLA) awarded a delivery order contract to AmerisourceBergen Drug Corp for the supply of Ofev 150 mg capsules (60-count units) valued at $8,590.58 under a firm fixed price arrangement. The contract was competitively awarded without a set-aside designation and is scheduled for completion by August 11, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office...
- SPE2DB22D2211Indefinite Delivery Contract
- SPE2DB22D2211-SPE2DB25FSFAPDelivery Order
The Defense Logistics Agency awarded a $17,181.16 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Ofev 150 mg capsules (60-count). The contract, which is not set-aside and was competitively awarded, has an ultimate completion date of October 7, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026, which serves as the primary pharmaceutical supply vehicle for military and federal healthcare systems worldwide. AmerisourceBergen Drug Corp is a major pharmaceutical distributor providing critical medical supplies to the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems. The company's extensive portfolio under its DLA contracts encompasses brand-name and generic medications, vaccines, medical devices, and specialized pharmaceuticals across multiple therapeutic domains. Ofev (nintedanib) is an antifibrotic agent used primarily in the treatment of idiopathic pulmonary fibrosis and other progressive fibrosing interstitial lung diseases, representing a specialized medical commodity consistent with the company's role as a primary vendor for federal pharmaceutical procurement.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $17.2k | 9/16/25 |